Skip to main content
. 2022 May 24;11(6):616. doi: 10.3390/pathogens11060616

Figure 6.

Figure 6

Pharmacokinetic simulation of UBMC-4. Simulation of UBMC-4 plasma concentrations over time after administration of multiple oral doses of (A) 2.5 mg every 12 h and (B) 2.0 mg every 24 h. Red line represents UBMC-4 in vitro half effective concentration, EC50, (0.774 µg/mL) on T. cruzi.